Therapeutic Advances in non-small cell Lung Cancer

Credit Area For Credit: Register/Login     View Activity As Guest

Release Date: Oct 6, 2010          Expiration Date: Oct 6, 2011



Program Description


Non-small cell lung cancer (NSCLC) can no longer be considered a homogenous disease. Histologic and molecular features of NSCLC provide important prognostic information and predict response to targeted therapy; therefore, therapy must be individualized according to these criteria to maximize patient outcomes. Maintenance therapy is being increasingly used in NSCLC instead of the traditional approach of first-line therapy, then waiting for disease progression. The staging system for NSCLC has been revised with respect to disease reclassification, likely impacting treatment approaches. The rapidly evolving treatment paradigm for NSCLC has generated practice gaps surrounding the best approaches to improve patient outcomes. This activity is designed to increase awareness of prognostic and predictive biomarkers in NSCLC and provide the necessary tools to select optimal individualized systemic frontline and maintenance therapies for NSCLC, based on histologic and molecular tumor features. In addition, participants will have a better understanding of the recently updated NSCLC staging system, which has important implications for approaches to disease management.

Faculty


Corey J. Langer, MD, FACP
Director of Thoracic Oncology
Abramson Cancer Center
Professor of Medicine
Hematology-Oncology Division
University of Pennsylvania
Philadelphia, PA
Read Biography

Mark A. Socinski, MD
Professor of Medicine
Multidisciplinary Thoracic Oncology Program
Lineberger Comprehensive Cancer Center
University of North Carolina
Chapel Hill, NC
Read Biography



University of Michigan Content Reviewer


Samuel M. Silver, MD, PhD
Professor, Division of Hematology/Oncology
Director, University of Michigan Cancer Center
Ann Arbor, MI



Target Audience


This activity is designed to meet the educational needs of medical oncologists, surgical oncologists, radiation oncologists, oncology nurses, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with NSCLC.

Educational Objectives


This activity was designed to address the following IOM competencies: provide patient-centered care; work in interdisciplinary teams; employ evidence-based practice.

At the conclusion of this activity, participants should be able to:

  • Select optimal individualized treatment approaches for non-small cell lung cancer (NSCLC) based on tumor histology, tumor molecular characteristics, and patient goals
  • Identify effective strategies for maintenance therapy in patients with NSCLC
  • Describe the revisions to the TNM staging system for NSCLC and the implications for patient management in the adjuvant and metastatic setting


Accreditation


The University of Michigan Medical School is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Michigan Medical School designates this educational activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Global Education Group is an approved provider of continuing nursing education by the Colorado Nurses Association, an accredited approver by the American Nurses Credentialing Centerâ??s Commission on Accreditation. This educational activity for 1.0 contact hours is provided by Global Education Group.



Disclosure Policy


University of Michigan Medical School (UMMS) and Global Education Group (Global) require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by UMMS and Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following relevant financial relationships that they or their spouse/partner have with commercial interests.

Mark A. Socinski MD: Speaker: Genentech, Eli Lilly; Grant/Research Support: Genentech, Eli Lilly, Pfizer, Abraxis, Celgene

Corey J. Langer, MD, FACP: Speakers Bureau: Eli Lilly, Genentech, OSI, Bristol-Myers Squibb, ImClone; Grant/Research Support: Bristol-Myers Squibb, Pfizer, Eli Lilly, ImClone, Genentech, OSI; Scientific Advisor: Bristol-Myers Squibb, Eli Lilly, ImClone, Sanofi-Aventis, Pfizer, Amgen, AstraZeneca, Novartis, Genentech, Bayer/Onyx, Abraxis, Abbott, Morphotek, Biodesix, Clarient, Caris Dx

Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Samuel M. Silver, MD, PhD (UMMS); Jackie Dawson, Amanda Glazar (Global); Paul Walden, Betsy Dennison, Jay Katz, Blair St. Amand (Rockpointe): Nothing to disclose



FDA Disclosure


The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

System Requirements


Please click here to access the system requirements to view the presentation.

By clicking the View/Register Button you are agreeing that you have read and understood the information on this page.



Sponsored By








Supported By


This activity is supported by educational grants from Genentech BioOncology, OSI Oncology, and Lilly USA, LLC. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.